🔗 Visit the ClinicalTrials.gov page for NCT01100242
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. | Immunotargets Ther | 2013 | 0.79 |
| 2 | Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma. | Oncologist | 2015 | 0.77 |